Literature DB >> 18023937

[Update on Clostridium difficile infections].

K Blanckaert1, B Coignard, B Grandbastien, P Astagneau, F Barbut.   

Abstract

PURPOSE: Clostridium difficile is an anaerobic gram positive, spore-forming bacterium which is responsible for 15-25% of antibiotic-associated diarrhea and for more than 95% of pseudomembranous colitis (PMC). This paper will review the main knowledge on C. difficile-associated infections and their recent evolution. CURRENT KNOWLEDGE AND KEY POINTS: Since 2003, outbreaks of severe C. difficile-associated diarrhea (CDAD) have been increasingly reported in Canada and the United States. This trend is assumed to be associated with the rapid emergence and spread of a specific clone of C. difficile belonging to PCR-ribotype 027 or North American Pulsotype 1, pulsotype (NAP1). This clone is characterized by the overproduction of toxins A and B and is positive for a third toxin named binary toxin. This clone has spread in UK, in Belgium, in the Netherlands, and, more recently, in France where it has been responsible for large outbreaks mainly in northern France. FUTURE PROSPECTS AND PROJECTS: A systematic reporting of C. difficile incidence by health facilities should enable a better assessment of this pathology in France.

Entities:  

Mesh:

Year:  2007        PMID: 18023937     DOI: 10.1016/j.revmed.2007.09.029

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  2 in total

1.  Impact of the Covid-19 pandemic context on the microbiological epidemiology and management of flexor sheath phlegmons.

Authors:  Pierrick Pirbakas; Charlotte Gabriel; Jacques Donatien; Lucian Stratan; Guillaume Odri; Stéphane Plawecki; Mathieu Pierre Severyns
Journal:  Orthop Traumatol Surg Res       Date:  2022-05-12       Impact factor: 2.425

Review 2.  Clostridium difficile associated infection, diarrhea and colitis.

Authors:  Perry Hookman; Jamie S Barkin
Journal:  World J Gastroenterol       Date:  2009-04-07       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.